Five key drug discovery deals of summer 2023
Drug Discovery World
AUGUST 9, 2023
The life sciences sector has seen significant M&A activity over the last few weeks. The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.
52 
Let's personalize your content